PITTSBURGH, Oct. 21 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for
Pramipexole Dihydrochloride Tablets, 0.125 mg, 0.25 mg, 0.5 mg, 1 mg and 1.5 mg, the generic version of Boehringer Ingelheim’s Mirapex® Tablets, a Parkinson’s disease treatment.
Pramipexole Dihydrochloride Tablets had U.S. sales of approximately $536 million for the 12 months ending June 30, 2010, according to IMS Health. Mylan Pharmaceuticals received final FDA approval for the 0.75 mg strength of Pramipexole Dihydrochloride Tablets on April 9, 2010. All strengths of the product are available for immediate shipment.
Currently, Mylan has 153 ANDAs pending FDA approval representing $95 billion in annual sales, according to IMS Health. Forty-five of these pending ANDAs are potential first-to-file opportunities, representing $24 billion in annual brand sales, for the 12 months ending June 30, 2010, according to IMS Health.
Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry’s broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world’s largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.
SOURCE Mylan Inc.
